Alton B. Kremer, VP, Clinical Research at PROGENICS PHARMACEUTICALS INC (PGNX), sold 875 shares at $21.60 ($19K) on 2006-06-21, disclosed to the SEC on 2006-06-26.
Scheduled sale ($19k) by VP, Clinical Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.